#USA #Boston #Stellaromics #Pyxa #Veronica Mankinen

Stellaromics Announces Major Executive Appointments

Stellaromics, Inc., a frontrunner in the 3D spatial multi-omics revolution, has made headlines with two significant additions to its executive team. Veronica Mankinen has been appointed as the Senior Vice President of Global Commercial Operations, while John Leamon, Ph.D., takes on the role of Senior Vice President of Product Development. These appointments come during an exciting period for the company, as it gears up for the commercial launch of its innovative Pyxa® platform, which promises to revolutionize spatial analysis of biological tissues.

Veronica Mankinen brings over two decades of commercial leadership experience in the life sciences sector. Her most recent role as Commercial General Manager at Abcam involved driving a remarkable turnaround, showcasing her capability to lead businesses effectively. Mankinen has also held global commercial leadership positions at notable organizations such as Emulate and Berkeley Lights. At Stellaromics, her primary responsibility will be to spearhead the global commercial strategy, overseeing the sales, marketing, and support teams that will drive the adoption of both the Pyxa platform and the company’s flagship products, STARmap™ and RIBOmap™.

Dr. John Leamon is recognized within the biotechnology community for his extensive experience in transforming innovative genomic platforms into market-ready products. Previously, he served as the Executive Director of Scientific Affairs at Meso Scale Diagnostics and has held senior roles at Qiagen and IsoPlexis. In his new position, Dr. Leamon will focus on ongoing product development, emphasizing innovation and scaling up the manufacturing of the Pyxa product line and its associated assays.

These executive changes align with Stellaromics’ strategic objective to enhance its foothold in the competitive market of 3D multi-omics, a field that combines vast datasets with sophisticated analysis to better understand biological processes. Todd Dickinson, Ph.D. and CEO of Stellaromics, noted, “This quarter marks a crucial point for our organization as we prepare to introduce Pyxa to global markets. Veronica and John's proven leadership in genomics and spatial biology will be vital in empowering researchers, thus broadening our reach and impact.”

The appointments of Mankinen and Leamon follow the recent inclusion of industry veterans Stacie Weninger and Steve McPhail to the Stellaromics Board of Directors. This highlights Stellaromics' commitment to strengthening its leadership as it transitions into a significant growth phase.

Founded with the vision to revolutionize the understanding of biological systems through cutting-edge multi-omics technologies, Stellaromics aims to provide researchers with state-of-the-art tools and solutions. Their commitment to fostering breakthroughs in health and science continues to drive their mission forward.

About Stellaromics

Stellaromics is a private entity headquartered in Boston, Massachusetts, dedicated to advancing the field of 3D spatial multi-omics. The company's innovative approach is focused on providing researchers with tools that facilitate insights into the complexities of biological systems, thereby enabling discoveries that ultimately aim to enhance human health and well-being. As it embarks on this new chapter, Stellaromics is poised to lead the way in the exciting landscape of genomics and spatial biology.